Cell line · CVCL_1547
Papers128
1 to 20 of 128
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| E3 ubiquitin ligase MAGI3‑mediated TAZ ubiquitination suppresses the non‑small cell lung cancer occurrence and development by targeting the Wnt pathway. | Int J Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Activation of PP2A-B56a leads to aberrant EGFR signaling and proliferative phenotypes in PDAC. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PARP inhibition enhances the antitumor activity of HER3-DXd in non-small cell lung cancer. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer. | Oncogene | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of cyclin-dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| HES1 inhibition overcomes CDK4/6 inhibitor resistance by targeting cancer stemness in lung adenocarcinoma. | J Exp Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Virtual Tumors Enable Prediction of Personalized Therapeutic Combinations for Non-Small Cell Lung Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting KRAS Codon 13 Mutations Using Direct Combination Approaches in Non-Small Cell Lung Cancer. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MPND Loss Epigenetically Activates TGFβ/SMAD3 Signaling to Drive Tumor Progression and Metastasis in Non-Small Cell Lung Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Functional genomic analysis reveals HAVCR1 as the key regulator of 5q33.3 locus linked to hyperlipidemia. | HGG Adv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the CHD3 chromatin remodeler exploits a synthetic lethal vulnerability in dual SMARCA4/SMARCA2-deficient cancers via derepression of PARD3B. | NPJ Precis Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MTFR2 promotes VDAC1 oligomerization to reprogram BCAA metabolism in tumor cells to polarize TAMs in LUAD. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Activation of GABBR1 by New Ligand Valerate Transcriptionally Regulates ATF4-NRF2-CXCL13 Axis Mediating CD8+ T Cell Anti-Tumor Immunity. | Int J Biol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| E2A selectively regulates TGF-β-induced apoptosis in KRAS-mutant non-small cell lung cancer. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| S6K1 Modulates STAT3 Activation to Promote Resistance to Radiotherapy in Lung Cancer. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Dual PD-1/IL-2Rα targeting restores CD8+ T cell fitness via STAT5/CD47 axis in SMARCA4-deficient NSCLC. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Lactylation Enhances the Activity of Lactate Dehydrogenase A and Promotes the Chemoresistance to Cisplatin Through Facilitating DNA Nonhomologous End Junction in Lung Adenocarcinoma. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Identification and Nonclinical Characterization of SAR444200, a Novel Anti-GPC3 NANOBODY T-cell Engager, for the Treatment of GPC3+ Solid Tumors. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Impact of MEK inhibition on T-cell infiltration and function after radiotherapy in KRAS-mutant lung cancer. | Front Immunol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| LT1-3, a Slit2-Derived Peptide, Exhibits Anti-Tumor Activity and Improves Cisplatin Therapy. | Cells | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1547/papers